Many readers may be interested in the above-titled article by Melinda Beck that appears in today’s Wall Street Journal.
Filed under: Uncategorized | Leave a Comment »
The Tuesday news reports: March 31, 2009
Posted on March 31, 2009 by Sitemaster
In today’s news there are reports on: Initial diagnosis of intraductal carcinoma of the prostate An aborted trial of HIFU using the Ablatherm device Late rectal complications after prostate brachytherapy
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Ablatherm, brachytherapy, carcinoma, complications, HIFU, high-intensity focused ultrasound, intraductal, rectal | Leave a Comment »
What the PCA3 test offers: an expert opinion
Posted on March 31, 2009 by Sitemaster
In an article on the web site of the Prostate Charity in the UK, Prof. Roger Kirby, an acknowledged expert on the diagnosis of prostate cancer in Europe, and the chairman of the Prostate Charity, has given his opinions on the potential of the PCA3 test.
Filed under: Diagnosis, Risk | Tagged: PCA3 test | Leave a Comment »
Two European studies suggest value of intermittent hormone therapy
Posted on March 30, 2009 by Sitemaster
Two European studies that have just been published appear to validate the long-term concept of intermittent hormone therapy (IHT).
Filed under: Management, Treatment, Uncategorized | Tagged: intermittent hormone therapy | 2 Comments »
HIFLA and the power of positive thinking
Posted on March 29, 2009 by Sitemaster
A patient newly diagnosed with what appears to be low risk, organ-confined disease told us yesterday that, “I am … using visualization techniques to attack the cancer cells as a secondary therapy while waiting for surgery.” We decided it would be helpful to share this important clinical technique with others.
Filed under: Living with Prostate Cancer, Management | Tagged: HIFLA, positive thinking | 4 Comments »
Salvage brachytherapy after definitive EBRT
Posted on March 28, 2009 by Sitemaster
The most common method for salvage therapy in men with recurrent, localized prostate cancer after first-line external beam radiation therapy (EBRT) is surgery. However, a newly published study reports one group’s experience with salvage permanent perineal radioactive-seed implantation (SPPI) as a possible therapeutic option for recurrent prostate adenocarcinoma after EBRT.
Filed under: Management, Treatment | Tagged: external beam radiation therapy, salvage brachytherapy | Leave a Comment »
The weekend news reports: March 28, 2009
Posted on March 28, 2009 by Sitemaster
Today’s reports include information on: Percentage of positive biopsy cores as a predictor for extraprostatic disease The RALP learning curve A surgical modification that improves recovery of continence Radiation toxicity associated with HDR brachytherapy + EBRT In a separate report we have dealt with a paper on the use of salvage brachytherapy for men with [...]
Filed under: Management, Treatment | Tagged: biopsy cores, continence, learning curve, radiation toxicity, RALP | Leave a Comment »
Some observations on the PLCO trial by the lead investigator
Posted on March 27, 2009 by Sitemaster
The March 26 issue of Record, a publication of Washington University in St. Louis, contains an article on the prostate cancer results from the PLCO screening trial, published in the New England Journal of Medicine last week. This article includes some specific comments from Gerry Andriole, MD, the lead author of the PLCO prostate cancer [...]
Filed under: Diagnosis, Risk | Tagged: risk, screening | Comments Off
Dana Jennings is back …
Posted on March 27, 2009 by Sitemaster
… with his latest offering entitled, “With a Buzz Cut, I Can Take On Anything.”
Filed under: Living with Prostate Cancer | Tagged: Dana Jennings | Comments Off
What Johns Hopkins has to say about the screening controversy
Posted on March 27, 2009 by Sitemaster
Many readers may be interested in seeing what Johns Hopkins has to say about the two studies published just over a week ago in the New England Journal of Medicine. This topic is addressed under the heading “Recent PSA Studies: What You Need To Know” in the latest issue of Health Alerts. Interestingly, in this [...]
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, risk, screening | 1 Comment »
Thinking “out of the box” — could vibration cause prostate cancer?
Posted on March 27, 2009 by Sitemaster
One should never criticize people just because they propose new ways of looking at old problems. And we have never come previously across the idea reported below as a contributing cause in the development of prostate cancer.
Filed under: Diagnosis, Prevention, Risk | Tagged: driving, risk, whole body vibration | 4 Comments »
Friday’s news reports: March 27, 2009
Posted on March 27, 2009 by Sitemaster
The reports addressed today offer information from three very technical studies dealing with: Genomic profiling of localized prostate cancers among African American men “DNA licensing” and prostate cancer progression Interleukin-6 over-expression and bicalutamide resistance
Filed under: Diagnosis, Drugs in development, Prevention, Risk | Tagged: African American, bicalutamide, DNA licensing, genomic profile, interleukin-6 | Leave a Comment »
AUA issues formal statement about PSA testing
Posted on March 26, 2009 by Sitemaster
12 US Representatives request greater focus on prostate-specific imaging research
Posted on March 26, 2009 by Sitemaster
On March 23, the following letter was sent by several members of the US House of Representatives to the acting director of the National Institutes of Health and the director of the National Cancer Institute:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: imaging, research | 5 Comments »
The Thursday news reports: March 26, 2009
Posted on March 26, 2009 by Sitemaster
This morning’s news report addresses items on: p53 overexpression and prostate cancer outcomes Diet and prostate cancer in newly diagnosed patients and prostate cancer survivors Outcomes of surgical treatment of men with clinical T1a and T1b disease Peripheral androgen ablation in men with biochemical recurrence after first-line treatment
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: diet, finasteride, flutamide, p53 overexpression, peripheral androgen blockade, T1a, T1b | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
